ArticleVaccine2013
Dengue dynamics and vaccine cost-effectiveness in Brazil.
Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- A systematic review of health economic evaluations of vaccines in Brazil.Human vaccines & immunotherapeutics · 2017Pooled it
- Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review.Health economics · 2016Pooled it
- Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey.PharmacoEconomics · 2015Pooled it
- Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.The American journal of tropical medicine and hygiene · 2017Trial
- Dengue as a Disease Threatening Global Health: A Narrative Review Focusing on Latin America and Brazil.Tropical medicine and infectious disease · 2023Review
- The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.PLoS neglected tropical diseases · 2020Article
- The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil.Bulletin of mathematical biology · 2020Article
- Hidden heterogeneity and its influence on dengue vaccination impact.Infectious Disease Modelling · 2020Article
- The Challenges Imposed by Dengue, Zika, and Chikungunya to Brazil.Frontiers in immunology · 2018Review
- An economic evaluation of vector control in the age of a dengue vaccine.PLoS neglected tropical diseases · 2017Article
- Determinants of felt demand for dengue vaccines in the North Caribbean region of Colombia.Annals of clinical microbiology and antimicrobials · 2017Article
- Cost-Effectiveness of Dengue Vaccination Programs in Brazil.The American journal of tropical medicine and hygiene · 2017Article
- The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.PharmacoEconomics · 2017Article
- Operations research in global health: a scoping review with a focus on the themes of health equity and impact.Health research policy and systems · 2017Article
- Spatial patterns of dengue cases in Brazil.PloS one · 2017Article
- Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model.PloS one · 2017Article
- Economic report on the cost of dengue fever in Vietnam: case of a provincial hospital.ClinicoEconomics and outcomes research : CEOR · 2017Article
- Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.The American journal of tropical medicine and hygiene · 2016Article
- Dengue serotype immune-interactions and their consequences for vaccine impact predictions.Epidemics · 2016Article
- Epidemiological Scenario of Dengue in Brazil.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Recent Phase 2b dengue vaccine trials have demonstrated the safety of the vaccine and estimated the vaccine efficacy with further trials underway. In anticipation of vaccine roll-out, cost-effectiveness analysis of potential vaccination policies that quantify the dynamics of disease transmission are fundamental to the optimal allocation of available doses. We developed a dengue transmission and vaccination model and calculated, for a range of vaccination costs and willingness-to-pay thresholds, the level of vaccination coverage necessary to sustain herd-immunity, the price at which vaccination is cost-effective and is cost-saving, and the sensitivity of our results to parameter uncertainty. We compared two vaccine efficacy scenarios, one a more optimistic scenario and another based on the recent lower-than-expected efficacy from the latest clinical trials. We found that herd-immunity may be achieved by vaccinating 82% (95% CI 58-100%) of the population at a vaccine efficacy of 70%. At this efficacy, vaccination may be cost-effective for vaccination costs up to US$ 534 (95% CI $369-1008) per vaccinated individual and cost-saving up to $204 (95% CI $39-678). At the latest clinical trial estimates of an average of 30% vaccine efficacy, vaccination may be cost-effective and cost-saving at costs of up to $237 (95% CI $159-512) and $93 (95% CI $15-368), respectively. Our model provides an assessment of the cost-effectiveness of dengue vaccination in Brazil and incorporates the effect of herd immunity into dengue vaccination cost-effectiveness. Our results demonstrate that at the relatively low vaccine efficacy from the recent Phase 2b dengue vaccine trials, age-targeted vaccination may still be cost-effective provided the total vaccination cost is sufficiently low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.